Bioton SA
WSE:BIO
Bioton SA
Other
Bioton SA
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioton SA
WSE:BIO
|
Other
-zł4.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
M
|
Mabion SA
WSE:MAB
|
Other
zł0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
R
|
Read Gene SA
WSE:RDG
|
Other
-zł10.3k
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genomed SA
WSE:GEN
|
Other
-zł4.9k
|
CAGR 3-Years
-27%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
U
|
Urteste SA
WSE:URT
|
Other
-zł55k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Synthaverse SA
WSE:SVE
|
Other
-zł2.6m
|
CAGR 3-Years
40%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
Bioton SA
Glance View
BIOTON SA engages in the manufacture and production of medicine and pharmaceutical substances. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 371 full-time employees. The company went IPO on 2005-03-16. The firm is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The firm's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.
See Also
What is Bioton SA's Other?
Other
-4.6m
PLN
Based on the financial report for Sep 30, 2025, Bioton SA's Other amounts to -4.6m PLN.
What is Bioton SA's Other growth rate?
Other CAGR 5Y
-3%
The average annual Other growth rates for Bioton SA have been 4% over the past three years , -3% over the past five years .
